Company intelligence / Profile preview

Nephronomics

Boston, Massachusetts, USA

Ownership: Private
Development stage: Other

Overview

Nephronomics has emerged from stealth to apply its proprietary AI-powered Nephronomics Atlas data platform, using whole genome sequencing combined with longitudinal clinical data from >35,000 CKM and renal patients, to discover novel targets and identify therapeutics for genetically defined subgroups. The company is still in the early discovery and partnering phase; no clinical results have been disclosed.[1][3][4]

Therapeutic areas: NephrologyCardiovascularMetabolic Disorders
Industry: Biotech

Partnerships

Fresenius Medical CareFrenovaGENEWIZ/Azenta Life Sciences

Beyond the preview

Go deeper on Nephronomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nephronomics.

Explore the full profile